THE Madras Pharmaceutical

Established in 1979, The Madras Pharmaceuticals is a prominent contract research and manufacturing services (CRAMS) organization headquartered in Chennai, India. Founded by five healthcare professionals, the company began with a modest 2,000 sq. ft. facility and a team of five employees. Over the decades, it has expanded significantly, now operating seven state-of-the-art manufacturing sites and employing over 3,000 individuals. The company specializes in producing a diverse range of pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic categories. With a turnover exceeding INR 500 crore, The Madras Pharmaceuticals has established itself as a leading player in the Indian pharmaceutical industry.

The company's ownership structure is a partnership, with key stakeholders including Mr. A.M. Sulaiman, Dr. Nagappan, Dr. Alagappan, and Mr. Kumaran. Mr. Sulaiman, a first-generation entrepreneur, serves as the Managing Director and has been instrumental in the company's growth and strategic direction. Dr. Nagappan and Dr. Alagappan, both renowned surgeons, play critical roles in the group's strategy and future growth planning. Mr. Kumaran, a committed pharmaceutical professional, heads the domestic business of the group, overseeing operations and business development.

The Madras Pharmaceuticals operates seven manufacturing facilities across India, each designed to produce a wide array of pharmaceutical formulations. These facilities are equipped to manufacture all dosage forms and therapeutic categories, ensuring versatility and capacity to meet diverse market demands. The company's flagship facility, established in 1979 in Chennai, has grown from an initial production capacity of 1 million tablets per month to 300 million tablets, 50 million capsules, 150,000 liters of liquids, and 0.75 tons of ointments annually.

In terms of capacity, the facilities collectively produce 3.6 billion tablets, 600 million capsules, 2,000 kiloliters of liquids, and 9 tons of creams and ointments annually. These facilities have received Good Manufacturing Practice (GMP) approvals from various regulatory bodies, including Digimed Peru, Ivory Coast, Ghana, Ethiopia, Kenya, Uganda, Tanzania, Nigeria, Malawi, Sri Lanka, Myanmar, Nepal, the Philippines, Cambodia, Zimbabwe, and the Commonwealth of Independent States (CIS) except Russia.

The leadership team at The Madras Pharmaceuticals comprises seasoned professionals with diverse expertise:

• Mr. A.M. Sulaiman: As the Managing Director and a co-founder, Mr. Sulaiman has been pivotal in the company's growth and strategic direction.

• Dr. Nagappan: A well-renowned orthopedic surgeon and co-founder, Dr. Nagappan plays a critical role in the group's strategy and future growth planning.

• Dr. Alagappan: A respected surgeon and co-founder, Dr. Alagappan is involved in the day-to-day affairs of the business, guiding the team in finance, legal, and logistics.

• Mr. Kumaran: Heading the domestic business, Mr. Kumaran started his career as a production chemist and has risen to oversee the domestic operations of the group.

• Dr. Vijay Alagappan: Holding a PhD in Biomedical Engineering and an MBA in Healthcare Management, Dr. Alagappan heads the international business and has been instrumental in achieving a compound annual growth rate (CAGR) of 30% in exports.

• Mr. Vijay Balakumar: With a background in IT and an MBA, Mr. Balakumar spearheads business development in emerging markets and focuses on the commercial operations of Steril-Gene to enhance supply efficiency.

The Madras Pharmaceuticals has made significant strides in penetrating regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's facilities have received GMP approvals from various regulatory bodies, facilitating market access in these regions. For instance, the Softgel and Sterilgene facilities are EU-GMP approved and were scheduled for US FDA inspection in 2019.

The company's commitment to quality and compliance is evident in its GMP accreditations from multiple countries, including Digimed Peru, Ivory Coast, Ghana, Ethiopia, Kenya, Uganda, Tanzania, Nigeria, Malawi, Sri Lanka, Myanmar, Nepal, the Philippines, Cambodia, Zimbabwe, and the Commonwealth of Independent States (CIS) except Russia.

These accreditations and approvals underscore The Madras Pharmaceuticals' dedication to meeting international standards, thereby enhancing its credibility and facilitating access to regulated markets.

The Madras Pharmaceuticals has strategically expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's facilities have obtained GMP approvals from various countries in these regions, including Digimed Peru, Ivory Coast, Ghana, Ethiopia, Kenya, Uganda, Tanzania, Nigeria, Malawi, Sri Lanka, Myanmar, Nepal, the Philippines, Cambodia, Zimbabwe, and the Commonwealth of Independent States (CIS) except Russia.

These approvals enable the company to supply quality pharmaceutical products to a broader global market, aligning with its mission to provide affordable and high-quality medicines worldwide.

The Madras Pharmaceuticals has adopted a diversified geographic strategy, establishing a robust presence in both domestic and international markets. With seven manufacturing facilities and a workforce exceeding 3,000 employees, the company has the capacity to produce a wide range of pharmaceutical formulations. The company's turnover of over INR 500 crore reflects its significant market presence.

This diversification mitigates concentration risk and positions the company to leverage growth opportunities across various regions. The strategic direction focuses on expanding market reach, enhancing production capabilities, and maintaining high-quality standards to meet the evolving needs of the global pharmaceutical industry.

The Madras Pharmaceuticals has demonstrated a commitment to meeting international regulatory standards, including those set by the U.S. Food and Drug Administration (FDA). The company's facilities have received GMP approvals from various regulatory bodies, facilitating market access in the United States. For instance, the Softgel and Sterilgene facilities were scheduled for US FDA inspection in 2019.

While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the company's proactive approach to obtaining GMP approvals indicates a strong commitment to compliance with FDA standards.

The Madras Pharmaceuticals has achieved Good Manufacturing Practice (GMP) accreditations from the World Health Organization (WHO) and the European Union (EU). The company's facilities have received EU-GMP approvals, and the Softgel and Sterilgene facilities were scheduled for US FDA inspection in 2019.

These accreditations underscore the company's dedication to maintaining high-quality manufacturing standards, ensuring that its products meet international regulatory requirements.

The Madras Pharmaceuticals operates in compliance with the regulations set forth by the Central Drugs Standard Control Organisation (CDSCO) and other Indian regulatory bodies. The company's facilities have obtained necessary approvals and licenses from the CDSCO, ensuring adherence to national standards for pharmaceutical manufacturing.

The company's commitment to quality and compliance is further demonstrated by its GMP accreditations from various countries, facilitating market access both domestically and internationally.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to The Madras Pharmaceuticals. The company's proactive approach to obtaining GMP approvals from various regulatory bodies suggests a strong commitment to maintaining compliance with international standards.

The Madras Pharmaceuticals operates in a competitive landscape, facing competition from both domestic and international pharmaceutical manufacturers. Key competitors include companies such as Cipla, Lupin, Sun Pharma, and USV, which also offer a wide range of pharmaceutical formulations across various therapeutic categories.

In the therapeutic categories of immunosuppressants, antibiotics, and cardiovascular drugs, The Madras Pharmaceuticals holds market